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Background: Bisphenol A (BPA) is an applied chemical that is used in many industrial fields and is a potential
endocrine disruption chemical (EDC) that is found in the environment. Bisphenol S (BPS) and polyethersulfone (PES)
have been suggested as putative BPA alternatives. In this study, the estrogenic potency induced by the binding of
17-beta-estradiol (E2), BPA, BPS, PES and their metabolites formed by the rat liver S9 fraction to the human estrogen
receptor (ER) was estimated.
Methods: We used an in vitro bioassay based on the luciferase reporter assay in MVLN cells to evaluate the
estrogenic activity of 17-beta-estradiol (E2), BPA, BPS, PES (E2: 0.001 to 0.3 nM; BPA, BPS and PES: 0.0001 to 5
microM) and their metabolites (E2: 0.05 microM; BPA, BPS and PES: 0.1 mM) according to incubation times (0, 20
and 40 min). After chemical treatment to MVLN cells for 72 hrs, and the cell viability and luciferase intensity induced
were estimated, from which the estrogenic activity of the chemicals tested was evaluated.
Results: BPA and BPS induced estrogenic activity whereas PES did not show any estrogenic activity in the
concentrations tested. In an in vitro assay of metabolites, BPA metabolites displayed comparable estrogenic activity
with BPA and metabolites of both BPS and PES showed increasing estrogenic activity.
Conclusions: The results suggest that the metabolites of BPS and PES have estrogenic potential and the need for
the assessment of both chemicals and their metabolites in other EDC evaluation studies. The estrogenic potency of
PES and its metabolites is the first report in our best knowledge.
Keywords: Endocrine disruptor, Bisphenol A, Bisphenol S, Polyethersulfone, MVLN cell, Estrogenic activity, S9
fraction, MetabolismBackground
According to the Environmental Working Group (www.
ewa.org), numerous chemicals have been produced and
used in the industrial, medical and agricultural areas,
and an average of 2,000 novel chemicals are registered
annually in the USA. There is a growing concern over
synthetic substances that have the potential to interfere
with endocrine systems and that subsequently impact
the maintenance of homeostasis, reproduction, develop-
ment and/or behavior in organisms by mimicking or* Correspondence: jwpark@kitox.re.kr
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[1]. These are commonly called endocrine disruption che-
micals (EDCs). The World Health Organization (WHO)
defines an EDC as an exogenous substance or mixture that
alters the function of the endocrine system and conse-
quently causes adverse health effects in an intact organism,
or its progeny, or (sub) populations [2]. The group of
EDCs is various and heterogeneous and includes industrial
materials and their by-products: dioxin, bisphenol A
(BPA), persistent organic pollutants (POPs), phthalates,
pharmaceutical agents and pesticides [3].
BPA, well-known EDC, has been widely used as a ma-
terial for the production of epoxy resins, phenol resins,d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 The structures of BPA, BPS and PES. BPA and BPS are
bisphenol analogues that have two hydroxyphenyl functionalities.
PES is a polymer of BPS.
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plastics for the packaging of foods (lacquered coating of
food cans) and drinks (polycarbonate bottles); and as a
thermal paper coating [4,5]. Some previous studies proved
that BPA was toxic to endocrine functions in organisms by
disrupting the ligand-activated estrogen receptor (ER)-me-
diated estrogenic activation [6-9]. Besides, BPA was re-
ported to increase the testosterone secretion and inhibit
the cancer resistance protein in the human and murine
cells [10]. Because of the potent endocrine toxicity of BPA,
the US Food and Drug Administration (FDA) warned of
the possible hazards of BPA to fetuses, infants and children
[11], and many countries, including the US, the members
of the EU and Canada, have restricted its use in products.
Due to the growing body of evidence on BPA toxicity,
there have been extensive efforts to find and replace
BPA with materials that are equally effective in its func-
tion but that are less toxic. Subsequently, bisphenol S
(BPS), tritan, polyethersulfone (PES) and polyethylene
terephthalate (PET) were proposed and considered to be
safe alternatives for BPA. BPS, a BPA analog, has been
broadly applied in the manufacture of resins and plastics
because it is stable at high temperatures and more resist-
ant to sunlight and biodegradation compared to BPA
[12,13]. Additionally, PES is currently used in industrial
resins and plastics because of its physical stability at
temperatures as high as 200°C [14]. However, their en-
vironmental suitability (i.e., less endocrine toxicity) to re-
place BPA used in products has not been thoroughly
investigated. Recently, some studies have reported that
BPS had a comparable weak estrogenic potency compared
with BPA, which in turn could disrupt E2-induced cell sig-
naling, leading to altered cell proliferation, cell death, and
prolactin release [13,15-17]. To the best of our knowledge,
there has been no study that evaluated the potential estro-
genic activity of PES; however, this chemical (or metabo-
lites) is likely to be estrogenic because it is a polymer form
of BPS [18,19]. Therefore, the degraded form or metabo-
lites of PES by physical and chemical reactions is likely to
have a similar structure to BPS.
Most chemicals are metabolized once absorbed into the
body, and some metabolites may have different chemical
features and toxic potency from the parent chemical [20].
BPA metabolites had a potent estrogenic activity [17,21]
and have been shown to enhance or decrease estrogenic
activity according to the metabolic pathways affected when
compared with BPA [20]. BPS metabolites produced by a
rat liver S9 fraction had a weak estrogenic activity in trans-
genic yeast when measured by β-galactosidase [22].
Grignard et al. suggested that the metabolites of BPS and
BPA might show different estrogenic activity with respect
to their respective parent chemicals, [15] implying the ne-
cessity of investigating endocrine disrupting capacity be-
tween the metabolites as well as the parent chemicals,which could help us to understand the comprehensive en-
vironmental suitability of the chemicals as BPA alternatives.
In the present study, we estimated the estrogenic ac-
tivities of BPA alternatives, BPS and PES, using a trans-
genic MVLN cell line that had a luciferase gene as the
reporter gene. Moreover, we assessed time-dependent
changes in the estrogenic activity of the metabolites of
the two BPA alternatives. Finally, we discussed the suit-




CAS number: 50-28-2, ≥98%), 2,2-bis (4-hydroxyphenyl)
propane (BPA, CAS number: 80-05-7, ≥99%) and 4,4'-
sulfonyldiphenol (BPS, CAS number: 80-09-1, 98%) were
purchased from Sigma-Aldrich (St Louis, MO, USA),
and polyethersulfone (PES, CAS number: 25608-6-3,
100%) was purchased from Goodfellow Cambridge
Limited (Cambridgeshire, UK). The structures of BPA,
BPS and PES were shown at Figure 1. All of the test che-
micals were dissolved in dimethyl sulfoxide (DMSO;
Junsei Chemical, Tokyo, Japan).
MVLN cells
The MVLN cell line used in this study was kindly do-
nated from Dr. Kyungho Choi at Seoul National Univer-
sity (Seoul, Republic of Korea). The MVLN cell line was
a stably transfected MCF-7 cell line, a human breast car-
cinoma cell line, with a luciferase reporter gene plasmid
consisting of a Xenopus laevis vitellogenin promoter re-
gion, which contains four estrogen responsive elements
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stream of the firefly luciferase reporter gene [23,24].
MVLN cells were cultured in Dulbecco’s Modified Ea-
gle’s media: Ham’s F12 nutrient mixture without phenol
red (Sigma-Aldrich, St Louis, MO, USA) containing so-
dium bicarbonate (Amresco, Solon, Ohio, USA), 10%
FBS (Hyclone, Logan, UT, USA), 1% Sodium pyruvate
(Sigma-Aldrich), 0.5 ml of insulin (1 mg/ml, Sigma-
Aldrich) and 1% (v/v) antibiotic solution (penicillin and
streptomycin, Invitrogen, Carlsbad, CA, USA). The cells
were incubated at 37°C in a 5% humidified CO2 incuba-
tor (Thermo Fisher Scientific, Waltham, MA, USA).
ER luciferase reporter gene assay
The ER binding assay is referred to in the OECD guide-
line for the testing of chemicals (OECD TG455, 2009)
and the previous study [25]. MVLN cells were prepared
in the assay medium (phenol red-free DMEM/F12 con-
taining 10% charcoal-dextran treated FBS (Hyclone)).
The 5 × 104 cells in 250 μl of assay media were seeded
on a 96-well white, clear bottom plate and were incu-
bated for 24 h at 37°C. After the 24 h incubation, serially
diluted stocks (30, 15, 7.5, 3.8, 1.9 and 0.1 nM of E2, and
500, 50, 5, 1, 0.1, and 0.01 μM of tested chemicals) were
dissolved in DMSO to generate final concentrations, and
chemicals were prepared. Each chemical stock solution
(2.5 μl of each) was used to treat 250 μl of cells (final
DMSO 1%, v/v): Final concentrations of tested chemi-
cals, 0.3, 0.15, 0.075, 0.038, 0.019 and 0.001 nM of E2,
and 5, 0.5, 0.05, 0.01, 0.001, and 0.0001 μM of BPA, BPS
and PES. The chemical-treated cells were incubated at
37°C for 72 h in a 5% CO2 incubator. Twenty microliters
of 5× CellTiter-Fluor™ Reagent (Promega, Madison, WI,
USA) was added to all of the tested cells, and the mix-
tures were briefly mixed by orbital shaking at 500 rpm
for 30 s. After incubation for 30 min at 37°C, cell via-
bility was measured by Synergy H1 microplate reader
(Bio-Tek, Winooski, VT, USA) at 380 nm (Ex) and
505 nm (Em). To evaluate the luciferase activity, 100 μl
of One-Glo™ Reagent (Promega) was added to all of the
tested cells, and the mixtures were incubated for 3 min
at room temperature. The luminescence intensity was
measured by Synergy H1 microplate reader (Biotek). All
treatments were independently triplicated and each
treatment was performed at three repeats.
Estimation of ER gene expression using quantitative
real-time PCR (qPCR)
To estimate the effect of ER expression by BPA, BPS
and PES, three chemicals (each 0.1 and 0.5 μM finally)
were treated with 1.25 × 105 cells on 6-well plate and in-
cubated at 37°C for 72 h in a 5% CO2 incubator. After
cell harvest, total RNA was extracted from the cells
using RNeasy mini kit (Qiagen, Hilden, Germany) andcDNA was synthesized using SuperScript III First-Strand
Synthesis System for RT-PCR (Invitrogen, Carlsbad, CA,
USA) according to manufacturer’s procedure.
The qPCR mixture (20 μl) was composed of 1 μl for-
ward primer (5 μM), 1 μl reverse primer (5 μM), 5 μl
cDNA (4 ng/μl), 10 μl 2× qPCR GO taq master mix
(Promega) and 3 μl sterile water. The qPCR was per-
formed at Agilent Mx3005P qPCR system (Agilent
Technologies, Wilmington, DE) as follows: 10 min at 95°
C (1 cycle), 20 sec at 95°C, 20 sec at 58°C and 20 sec at
72°C for 40 cycles, followed by a dissociation step for
10 sec at 95°C, 10 sec at 55°C and 10 sec at 95°C for
1 cycle. The primers of ER and β-actin as reference gene
were referred from Kurebayashi et al. and Al-Bader et al.
[25,26]. Relative transcriptional level was estimated by
2ΔΔCt method [27]. The PCR efficiency was determined
on 90–110% under optimized qPCR conditions and the
product specificity was checked by the dissociation curve
analysis. All experiments were triplicated. The transcrip-
tional levels among treatments were statistically analyzed
by one-way analysis of variance (ANOVA) followed by
the post hoc comparison, Least Significant Difference
(LSD) test using the SPSS software (SPSS v20, IBM,
Armonk, NY, USA) (p <0.05).
Incubation of chemicals with S9 fraction
To evaluate the estrogenic activities of the metabolites
of BPA, BPS and E2, their respective parent chemical
was incubated with a rat liver S9 fraction (Gibco,
Carlsbad, CA, USA) according to the method described
in the previous study [22]. Each 0.1 M parent compound
(but E2 is 0.05 μM) was incubated in 80 μl of 0.1 M po-
tassium phosphate buffer (pH 7.4) containing 0.25 mg/
ml of the rat liver S9 fraction and 1% DMSO at 37°C for
5 min. The reaction was initiated by adding 20 μl of a
NADPH-generating system (BD Gentest, Franklin Lakes,
NJ, USA) to the final 100 μl reaction volume and was in-
cubated, with shaking, at 37°C for 40 min. Each reaction
mixture without the 40 min shaking-incubation after
adding acetonitrile was used as a negative control (inac-
tivated S9). The quenched reaction mixtures that were
generated by the addition of 50 μl of acetonitrile were
placed on ice for 15 min and were centrifuged at
18,000 × g for 5 min at 4°C. The supernatants were
transferred to new tubes and completely evaporated using
Scanspeed 32 (Labogene Aps, Copenhagen, Denmark).
The extracts were dissolved in 50 μl of DMSO. Each sam-
ple solution (2.5 μl) was applied for assessment by the es-
trogenic activity assay.
Estrogenic activity of PES revealed in acetonitrile
PES is known to attack by some organic solvents such as
acetone and acetonitrile. In the metabolism procedure,
because acetonitrile was used to stop the metabolism,
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attacking of solvent induced the estrogenic activity.
Thus, we tried to estimate the estrogenic potency of PES
treated on acetonitrile. PES was treated with or without
50 μl of acetonitrile for 15 min in ice. The estrogenic ac-
tivity of PES treated with or without acetonitrile was
performed by the procedure described above.
Data and statistical analysis
The estrogenic activity of the tested chemicals was cal-
culated by comparing each luciferase activity obtained as
the mean relative luminescence units (RLU) to that of
the solvent control. The effective concentration (EC)
values and relative potency (REP) were calculated by the
method referred to by Villeneuve et al. [28]. To estimate
the EC values and REPs of the tested chemicals with re-
spect to estrogenic activity of E2, a standard curve of
each test chemical was constructed by using normalized
luciferase units (i.e., RLUs of test chemical – RLUs of
solvent control) and converting these values to a per-
centage of the mean maximum response of E2. Differ-
ences among each chemical was analyzed by one-way
analysis of variance (ANOVA), followed by the post hoc
comparison Least Significant Difference (LSD) test using
the SPSS software (SPSS v20, IBM, Armonk, NY, USA)
and a t-test using the Sigma Plot software (Systat Soft-
ware, Chicago, IL, USA). Differences were considered
statistically significant at p <0.05. The data represent the
mean values of three independent experiments that were
performed in triplicate.
Results
Estrogenic activities of tested chemicals
From the several concentrations of E2, BPA, BPS and
PES, the luciferase activities (RLU, relative light unit)
were obtained and were calculated for REP against the
maximum luciferase activity of 0.3 nM E2, which was
the maximum tested concentration of E2 (E2max). In
the highest concentration (5 μM) of BPA, BPS and PES,
the death cell (in BPA and BPS) and chemical aggrega-
tion (in PES) were observed, thus the result in this con-
centration was excluded to calculate REP. The
relationship of E2 was determined by comparing to
E2max using the REP values (see Additional file 1: Figure
S1), from which each EC20, EC50 and EC80 value was esti-
mated (Table 1). The estrogenic activity of BPA increasedTable 1 The effective concentration (EC) values of E2,
BPA and BPS
E2 (μM) BPA (uM) BPS (uM)
EC20 5.08 × 10
−7 6.38 × 10−1 6.14 × 101
EC50 1.05 × 10
−5 6.70 × 101 6.97 × 105
EC80 2.18 × 10
−4 7.04 × 103 7.90 × 109by a dose–response manner statistically and that of BPS
also was shown the increasing tendency although there
was little of statistical difference (Figure 2). No estrogenic
activity was observed at two low concentrations (1 and 0.1
nM) of BPA and BPS. PES showed no estrogenic activity
in all of the concentration ranges tested (data was not
shown). In the highest concentration of both BPA and BPS
(0.5 μM), 48.8% REP of BPA and 19.2% REP of BPS were
shown, respectively (Figure 2 and Table 2). By comparingFigure 2 The luciferase activity of BPA, BPS and PES according
to the exposure concentrations. The activity ratio was measured
by compare to the luciferase activity of the highest concentration
(E2max). Data represent the mean ± SD were statistically analyzed by
ANOVA followed by the Least Significant Difference (LSD) test (p <0.05).
All tests were performed in triplicate.
Table 2 Maximum concentrations of individual compounds tested in MVLN in vitro bioassays, induction relative to an








BPA 0.5 48.8 4.25 × 10−5 2.17 × 10−4 – 8.32 × 10−6
BPS 0.5 19.2 4.09 × 10−9 2.25 × 10−6 – 7.41 × 10−12
PES 0.5 - NAd
a%-E2max =Maximum response against the response at the highest concentration of E2 (E2max).
bSingle point estimate of REP performed for the response of 50%-E2max.
cREPs reported as the range of REP estimates generated from multiple points over a response range from 20- to 80%-E2max.
dNA: not analyzed because the dose–response relationship was insufficient for estimation.
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REP50 and REP80 of both BPA and BPS were estimated,
and were summarized in Table 2. The REP50 of BPA and
BPS was 4.25 × 10−5 and 4.09 × 10−9, respectively, and
REP20–80 was 2.17 × 10
−4 to 8.32 × 10−6 and 2.25 × 10−6 to
7.41 × 10−12, respectively.Gene expression level of the estrogen receptor
ER gene expression level induced by BPA, BPS and PES
was compared to that by solvent (1% DMSO) (Figure 3).
All of three chemicals did not affected ER gene expres-
sion level.Estrogenic activities of the metabolites
The estrogenic activities of E2 metabolites according to
incubation times (20 and 40 min) with an active rat liver
S9 fraction were 85 and 68%, respectively, when com-
pared to that of E2 incubated at 0 min (using an inactive
rat liver S9 fraction) (Figure 4). The estrogenic activities
of BPA, BPS and PES metabolites also changed accord-
ing to the incubation times (Figure 5). A difference in
the estrogenic activity between acetonitrile-treated PESFigure 3 The relative ER gene expression level induced by BPA,
BPS and PES exposure in MVLN cell. The ER gene expression level
of MVLN cell treated with BPA, BPS and PES was not statistically
different each other. The data were statistically analyzed by ANOVA
followed by LSD test (p <0.05). All tests were performed in triplicate.and –untreated PES was not observed (data are not
shown).
Discussion
EDCs directly or non-directly affect the endocrine sys-
tem through diverse mechanisms. Among many mecha-
nisms, some chemicals choose an estrogenic strategy to
mimic natural estrogens that directly bind to the ER and
subsequently generate the unexpected endocrinal pro-
cesses. Most studies have evaluated the estrogenic activ-
ity of intact chemicals and have frequently ignored the
evaluation of their metabolites formed within the body.
Once taken into body, the chemicals are catalyzed or
metabolized by several enzymes such as oxygenases, hy-
drogenases and transferases. The metabolites of some
estrogenic chemical by the S9 fraction showed a differ-
ent level of estrogenic potency when compared to their
original chemicals [17,21,22]. Thus, in the EDC risk as-
sessment, the estrogenic activity of metabolites must be
evaluated as well as their intact chemicals.Figure 4 The relative estrogenic activity of E2 metabolites
compared to intact E2 incubated with an acetonitrile-denatured
inactivated S9 fraction (inactive S9). E2 (0.05 uM) was incubated
with rat liver S9 for 0, 20 and 40 min at 37°C. Data represent the
mean ± SD of four experiments and were statistically analyzed by
ANOVA followed by LSD test (p <0.05). All tests were performed
in triplicate.
Figure 5 The estrogenic activities of the metabolites of BPA,
BPS and PES formed by rat liver S9 fractions according to
incubation times. The BPA, BPS and PES (0.1 mM, respectively)
were incubated with rat liver S9 for 0 (inactive S9), 20 and 40 min at
37°C. The difference among incubation times of each chemical was
statistically analyzed by ANOVA followed by LSD test (p <0.05). All
tests were performed in triplicate.
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known estrogenic disruptor as an ER agonist but not an
antagonist. BPA binds to ER, and the BPA-ER complex
induces various unexpected endocrinal effects such as
birth defects, reproductive, developmental, immune disor-
ders and hormone-related cancers [29-33]. Because of its
potent estrogenic disruption, the efforts to restrict its util-
ity have been made and new BPA alternatives have been
suggested. Among them, BPS has been recommended as
one of BPA alternatives because it has a thermal resistance
and a similar structure with BPA (Figure 1). Moreover,
PES which is a polymer form of BPS linked by ether bonds
has been also suggested as one of BPA alternatives
(Figure 1). In the present study, we evaluated the estro-
genic potency of E2, BPA, BPS and PES, and also assessed
the estrogenic potential of each metabolite formed by rat
liver S9 fraction.
In a primary dose–response ER binding assay, E2
showed estrogenic activity in all of the concentrations
tested (Additional file 1: Figure S1). This is similar to the
results of E2 estrogenic activity of other studies, indicat-
ing that the ER binding assay using the MVLN cell line
in the current study was credible. Besides, the result of
ER gene expression using real-time PCR supported that
the estrogenic activity generated by chemical treatment
was induced by ER binding but not overexpression of ER
gene (Figure 3).
The estrogenicity of metabolized E2 by the rat liver S9
fraction was estimated and compared with intact E2.
The estrogenic activity of E2 metabolites was decreased
according to incubation times, which is in accordancewith previous studies showing that E2 had a higher es-
trogenic activity than all of its metabolites. This result
implies that the estrogenic potency of chemical can be
changed by metabolism. In contrast to E2, BPA metabo-
lites produced by the rat liver S9 fraction were known to
show stronger estrogenic activity than BPA [15,20].
Among the BPA metabolites, 4-methyl-2,4-bis (4-hydro-
xyphenyl) pent-1-ene (MBP) was suggested to generate
estrogenic activity [17] and induced estrogenic effects in
exposed organisms such as vitellogenin induction in the
male medaka (Oryzias latipes) [34] and estrogen receptor
mRNA induction in the rat [35]. In our study, however,
the estrogenic activity of BPA metabolites decreased. At
60 min incubation, the estrogenic activity was shown to be
comparable with 0 time (data was not shown), indicating
that the estrogenic metabolites were not generated within
incubation time of our study. Although our result was dif-
ferent from the previous studies, estrogenic studies for
BPA metabolites showed that the derivatives produced by
metabolism had a different estrogenicity from BPA, sug-
gesting the requirement of an estrogenic assay for metabo-
lites with intact chemicals.
BPS has similar physical and chemical features to BPA,
but the estrogenic activity of BPS was much lower than
that of BPA at tested concentration of this study (Ta-
bles 1 and 2) different from the previous study reported
that the estrogenic potencies of BPA and BPS were com-
parable [15]. But, BPS showed the similar estrogenic ac-
tivity to BPA in high concentration (see the 0 min of
Figure 5). However, BPS showed dose-dependent estro-
genic activity in the range of tested concentrations and
the estrogenic activity of its metabolites also increased in
some incubation time. This implies that BPS is not suit-
able as a BPA alternative. Similarly, in previous study,
the estrogenic activity of the BPS metabolites that were
measured using the yeast two-hybrid system and fluores-
cence polarization system increased after a 60 min incu-
bation with the S9 fraction [22]. Although there is no
study of metabolites of BPS formed by S9 fraction, if
BPS is metabolized like BPA, the dimer of phenol with
the sulfonyl group formed by metabolism of S9 fraction
was supposed as the estrogenic chemical.
In dose–response assay, BPA and BPS induced estro-
genic activity whereas PES did not show any estrogenic
activity at the concentrations evaluated (500 to 0.1 nM).
PES is a polymer form having a long length and large
size (approximately 55,000 MW). Thus, it is considered
that it is not easy to bind to the ER, causing little estro-
genic activity. But biologically or chemically degraded
PES may have an EDC potential as like BPS because PES
is synthesized by the nucleophilic polycondensation of
both BPS and 4,4′-dichlorodiphenylsulfone at high temper-
atures in the presence of potassium carbonate [18]. In
current study, the estrogenic activity of the PES metabolites
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weak estrogenic activity was also observed at high concen-
tration (0.1 mM) of PES (in the dose response assay, the
highest concentration of PES was 5 μM). Because some
polar organic solvents such as acetone and acetonitrile can
break the chain of PES (www.spectrumlabs.com/dialysis/
Compatibility.html and www.coastpneumatics.com/chemres.
html), it is not recommended that PES products be treated
with these solvents [36,37]. Since acetonitrile was used
to stop the metabolism by inhibition of S9 fraction, we
considered that PES treated with acetonitrile generated
estrogenic activity, thus the experiment to verify the estro-
genic activity of the acetonitrile-treated PES was tried. But
acetonitrile-treated PES showed similar estrogenic activity
to acetonitrile-untreated PES, indicating that exposure for
a short time in acetonitrile did not induce the estrogenic
activity of PES. Some previous studies reported that the
estrogenic activity was induced by BPA released from a
bottle products of the polycarbonate synthesized by a re-
action of BPA and phosgene [38,39]. Similar to BPA, the
estrogenic activity of PES is suggested be caused by releas-
ing a monomer or small sized polymer. In low concentra-
tions, the amount of the estrogenic materials (monomer
or shorter PES) was not enough to measure the estrogenic
activity, but sufficient estrogenic materials seemed to
present in high concentrations. During chemical treatment
in the cell (72 h), the estrogenic monomer or small poly-
mer would be released from PES and subsequently induced
estrogenic activation by binding to ER. Actually, Simoneau
et al. tried to detect the releases from PES on the simulant
for milk 50% EtOH (as per Commission Regulation No.
321/2011 of 1 April 2011) and they certified that diphenyl
sulphone was released from PES [19]. But bisphenol S was
not detected. Although there is no knowledge that diphe-
nyl sulphone is an estrogenic chemical, this result suggests
the potential of releasing of estrogenic chemicals from PES
on other conditions. In addition, PES metabolites showed
stronger estrogenic activity compared to intact PES, indi-
cating that PES was metabolized to other chemicals having
estrogenic activity. The PES metabolites showed compar-
able activity to BPS metabolites. There is no knowledge of
PES metabolism and its metabolites, but some natural
polymers formed by ether bonds such as dextran and chi-
tosan are known to enzymatically degrade [40], suggesting
that PES is also able to cleave biologically. Our study pro-
vides the evidence that PES and PES metabolites have the
estrogenic potency, which is the first report within our
knowledge. Also, we hope that the estrogenic metabolites
of PES will be identify in the further study.
Conclusions
In this study, the estrogenic potencies of bisphenol deriva-
tives (BPA, BPS and PES) and their metabolites generated
by the rat liver S9 fraction were evaluated using an in vitroluciferase assay with transgenic MVLN cell lines. We veri-
fied the estrogenic activity of E2 and BPA and their metabo-
lites. Also, we observed the estrogenic potency of not only
BPS and PES suggested as BPA alternatives but also their
metabolites. These results explain that the estrogenic activity
of chemicals is able to be changed by metabolism and show
the hazardous potency of BPS, PES and their metabolites as
endocrine disruptors. Moreover, this study insist that the
assessment of both parent chemicals and their metabolites
is needed in future EDC evaluation studies.
Additional file
Additional file 1: Figure S1. The standard curve generated from the
luciferase activity induced by E2 on MVLN cell. Data were presented as
the mean values of luciferase activity induced by E2. Each data point
represents the mean values of three independent experiments
performed in triplicate.
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